← ONCSM overview

ONCOSEM ONKOLOJİK SİSTEMLER (ONCSM) — Income Statement

Detailed income statement with YoY comparison · latest 9A26

Income statement and cash flow are cumulative (6A = 6-month cumulative, 12A = full year). YoY Δ compares the same period last year.

Line item9A266A263A2612A259A256A25YoY Δ
Hasılat809.9M477.5M239.0M709.1M523.4M341.9M+54.8%
Satışların Maliyeti-393.0M-218.2M-108.7M-389.2M-328.8M-227.2M+19.5%
TİCARİ FAALİYETLERDEN BRÜT KAR (ZARAR)416.9M259.3M130.3M319.8M194.5M114.7M+114.3%
BRÜT KAR (ZARAR)416.9M259.3M130.3M319.8M194.5M114.7M+114.3%
Genel Yönetim Giderleri-170.6M-106.7M-63.5M-137.3M-112.8M-71.9M+51.3%
Pazarlama Giderleri-33.9M-23.4M-10.4M-24.3M-16.2M-9.7M+109.6%
Araştırma ve Geliştirme Giderleri-9.9M-5.1M-504K-1.2M-808K—+1121.2%
Esas Faaliyetlerden Diğer Gelirler1.6M1.5M921K3.6M2.9M1.6M-44.1%
Esas Faaliyetlerden Diğer Giderler-9.7M-3.1M-3.3M-6.6M-6.2M-2.9M+55.9%
ESAS FAALİYET KARI (ZARARI)194.6M122.4M53.6M154.0M61.5M31.8M+216.2%
Yatırım Faaliyetlerinden Gelirler171K42K42K422K422K206K-59.3%
FİNANSMAN GELİRİ (GİDERİ) ÖNCESİ FAALİYET KARI (ZARARI)194.7M122.4M53.6M154.5M62.0M32.0M+214.3%
Finansman Gelirleri1.6M1.6M963K9.0M7.5M5.6M-78.7%
Finansman Giderleri-51.8M-36.7M-18.8M-34.7M-24.7M-13.4M+109.6%
Net Parasal Pozisyon Kazançları (Kayıpları)-54.4M-37.6M-23.3M-55.4M-30.8M-24.5M+76.6%
SÜRDÜRÜLEN FAALİYETLER VERGİ ÖNCESİ KARI (ZARARI)90.1M49.9M12.5M73.4M13.9M-404K+546.5%
Sürdürülen Faaliyetler Vergi (Gideri) Geliri-29.5M-18.9M-6.6M-23.0M11.6M8.5M—
Dönem Vergi (Gideri) Geliri-40.9M-21.1M—-9.7M———
Ertelenmiş Vergi (Gideri) Geliri11.3M2.3M-6.6M-13.3M11.6M8.5M-2.3%
SÜRDÜRÜLEN FAALİYETLER DÖNEM KARI (ZARARI)60.5M31.0M5.9M50.4M25.5M8.1M+137.2%
DÖNEM KARI (ZARARI)60.5M31.0M5.9M50.4M25.5M8.1M+137.2%
Kontrol Gücü Olmayan Paylar000000—
Ana Ortaklık Payları60.5M31.0M5.9M50.4M25.5M8.1M+137.2%
Sürdürülen Faaliyetlerden Pay Başına Kazanç250.0M—20.0M————
Pay Başına Kazanç—130.0M—————

ONCOSEM ONKOLOJİK SİSTEMLER (ONCSM) Income Statement

ONCOSEM ONKOLOJİK SİSTEMLER (ONCSM) Income Statement

This page shows the income statement of ONCOSEM ONKOLOJİK SİSTEMLER SANAYİ VE TİCARET A.Ş. (ONCSM) as reported to the Turkish Public Disclosure Platform (KAP), broken down line by line across the most recent periods, with year-over-year percentage change so you can compare each figure to the same period last year.

Latest period 9A26: TİCARİ FAALİYETLERDEN BRÜT KAR (ZARAR): 416.9M TL (YoY +114.3%) · BRÜT KAR (ZARAR): 416.9M TL (YoY +114.3%) · ESAS FAALİYET KARI (ZARARI): 194.6M TL (YoY +216.2%).

How to read this statement

The income statement and cash flow statement are cumulative: the 6-month column covers the first two quarters combined, the 9-month column the first three, and the full-year column all four. Compare each period to the same period last year (YoY) for a like-for-like view.

Frequently Asked Questions

Where does ONCSM's income statement data come from?

The figures are sourced from ONCOSEM ONKOLOJİK SİSTEMLER SANAYİ VE TİCARET A.Ş.'s official quarterly financial statements filed with KAP (the Turkish Public Disclosure Platform) and updated automatically after each new disclosure.

Is the income statement cumulative or per quarter?

The income statement and cash flow statement are cumulative within the year (6-month, 9-month, full-year), matching the official filings.

Is ONCSM financial data free on Borsafolio?

Yes. Balance sheet, income statement and cash flow statements for every BIST company are free and require no signup.